{"id":1008293,"date":"2026-10-07T11:02:14","date_gmt":"2026-10-07T15:02:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/"},"modified":"2026-10-07T11:02:14","modified_gmt":"2026-10-07T15:02:14","slug":"wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/","title":{"rendered":"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Oct.  07, 2026  (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (\u201cXenon\u201d) common stock (NASDAQ: XENE).<\/p>\n<p align=\"justify\">Xenon is a clinical-stage drug company developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD.<\/p>\n<p align=\"justify\">After the market closed on September 17, 2026, Xenon announced a voluntary pause in new patient enrollment in its ongoing clinical studies in MDD and bipolar depression following an analysis of neuropsychiatric adverse events in those studies. Following this announcement, Xenon\u2019s stock price fell $17.60 per share, or 30.7%, to close at $39.75 on September 18, 2026, on very heavy trading volume.<\/p>\n<p align=\"justify\">Investors who suffered losses trading Xenon common stock and would like to discuss the investigation are encouraged to contact Adam Savett at (212) 451-9655 or asavett@wolfpopper.com.<\/p>\n<p align=\"justify\">Wolf Popper has recovered billions of dollars for defrauded investors. Courts have repeatedly recognized the firm\u2019s reputation and expertise by appointing it to major roles in securities litigation. For more information about Wolf Popper, please visit www.wolfpopper.com.<\/p>\n<p align=\"justify\">May Be Considered Attorney Advertising in Certain Jurisdictions. <br \/>Prior Results Do Not Guarantee a Similar Outcome.<\/p>\n<p align=\"justify\">Wolf Popper LLP<br \/>Adam Savett, Esq.<br \/>570 Lexington Avenue<br \/>New York, NY 10022<br \/>Tel.: (212) 451-9655<br \/>Email: asavett@wolfpopper.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWQ2OTZiZjUtODk3OC00NTk2LTllMmEtYWIzZWJhYTUwNmE3LTEwMjkyMTktMjAyNi0xMC0wNy1lbg==\/tiny\/Wolf-Popper-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (\u201cXenon\u201d) common stock (NASDAQ: XENE). Xenon is a clinical-stage drug company developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD. After the market closed on September 17, 2026, Xenon announced a voluntary pause &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1008293","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (\u201cXenon\u201d) common stock (NASDAQ: XENE). Xenon is a clinical-stage drug company developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD. After the market closed on September 17, 2026, Xenon announced a voluntary pause &hellip; Continue reading &quot;Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-07T15:02:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors\",\"datePublished\":\"2026-10-07T15:02:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/\"},\"wordCount\":268,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/\",\"name\":\"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=\",\"datePublished\":\"2026-10-07T15:02:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/","og_locale":"en_US","og_type":"article","og_title":"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors - Market Newsdesk","og_description":"NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP continues to investigate potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (\u201cXenon\u201d) common stock (NASDAQ: XENE). Xenon is a clinical-stage drug company developing azetukalner (formerly XEN1101), its lead drug candidate, for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. Azetukalner is a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. In January 2025, Xenon announced the initiation of its Phase 3 X-NOVA2 trial, designed to enroll approximately 450 patients to evaluate a 20-mg dose of azetukalner against placebo for the treatment of MDD. After the market closed on September 17, 2026, Xenon announced a voluntary pause &hellip; Continue reading \"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-07T15:02:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors","datePublished":"2026-10-07T15:02:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/"},"wordCount":268,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/","name":"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=","datePublished":"2026-10-07T15:02:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0MTQzNCM3ODgzOTA5IzIwMTc2NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-continues-investigation-on-behalf-of-xenon-pharmaceuticals-inc-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wolf Popper LLP Continues Investigation on Behalf of\u00a0Xenon Pharmaceuticals Inc. Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1008293"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1008293\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1008293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1008293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1008293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}